OTCMKTS:NNBP

Nanobac Pharmaceuticals Competitors

$0.0018
0.00 (0.00 %)
(As of 05/10/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
$0.01
Volume432,800 shs
Average Volume655,286 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta-0.24

Competitors

Nanobac Pharmaceuticals (OTCMKTS:NNBP) Vs. ACUS, AFFY, ARYX, AHROQ, CBPI, and CDSG

Should you be buying NNBP stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Nanobac Pharmaceuticals, including Acusphere (ACUS), Affymax (AFFY), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), China Botanic Pharmaceutical (CBPI), and China Dongsheng International (CDSG).

Acusphere (OTCMKTS:ACUS) and Nanobac Pharmaceuticals (OTCMKTS:NNBP) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Profitability

This table compares Acusphere and Nanobac Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcusphereN/AN/AN/A
Nanobac PharmaceuticalsN/AN/AN/A

Risk & Volatility

Acusphere has a beta of -0.25, indicating that its stock price is 125% less volatile than the S&P 500. Comparatively, Nanobac Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the S&P 500.

Earnings & Valuation

This table compares Acusphere and Nanobac Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcusphereN/AN/AN/AN/AN/A
Nanobac PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for Acusphere and Nanobac Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acusphere0000N/A
Nanobac Pharmaceuticals0000N/A

Summary

Nanobac Pharmaceuticals beats Acusphere on 1 of the 1 factors compared between the two stocks.

Affymax (OTCMKTS:AFFY) and Nanobac Pharmaceuticals (OTCMKTS:NNBP) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Earnings & Valuation

This table compares Affymax and Nanobac Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AffymaxN/AN/AN/AN/AN/A
Nanobac PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for Affymax and Nanobac Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Affymax0000N/A
Nanobac Pharmaceuticals0000N/A

Profitability

This table compares Affymax and Nanobac Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AffymaxN/AN/AN/A
Nanobac PharmaceuticalsN/AN/AN/A

Risk & Volatility

Affymax has a beta of 2.77, indicating that its stock price is 177% more volatile than the S&P 500. Comparatively, Nanobac Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the S&P 500.

Summary

Affymax beats Nanobac Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Nanobac Pharmaceuticals (OTCMKTS:NNBP) and ARYx Therapeutics (OTCMKTS:ARYX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

This table compares Nanobac Pharmaceuticals and ARYx Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nanobac PharmaceuticalsN/AN/AN/AN/AN/A
ARYx TherapeuticsN/AN/AN/AN/AN/A

Risk and Volatility

Nanobac Pharmaceuticals has a beta of -0.24, indicating that its share price is 124% less volatile than the S&P 500. Comparatively, ARYx Therapeutics has a beta of -0.53, indicating that its share price is 153% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Nanobac Pharmaceuticals and ARYx Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nanobac Pharmaceuticals0000N/A
ARYx Therapeutics0000N/A

Profitability

This table compares Nanobac Pharmaceuticals and ARYx Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nanobac PharmaceuticalsN/AN/AN/A
ARYx TherapeuticsN/AN/AN/A

Summary

Nanobac Pharmaceuticals beats ARYx Therapeutics on 1 of the 1 factors compared between the two stocks.

Nanobac Pharmaceuticals (OTCMKTS:NNBP) and AtheroNova (OTCMKTS:AHROQ) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for Nanobac Pharmaceuticals and AtheroNova, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nanobac Pharmaceuticals0000N/A
AtheroNova0000N/A

Profitability

This table compares Nanobac Pharmaceuticals and AtheroNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nanobac PharmaceuticalsN/AN/AN/A
AtheroNovaN/AN/AN/A

Risk & Volatility

Nanobac Pharmaceuticals has a beta of -0.24, indicating that its share price is 124% less volatile than the S&P 500. Comparatively, AtheroNova has a beta of -8.71, indicating that its share price is 971% less volatile than the S&P 500.

Valuation & Earnings

This table compares Nanobac Pharmaceuticals and AtheroNova's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nanobac PharmaceuticalsN/AN/AN/AN/AN/A
AtheroNovaN/AN/AN/AN/AN/A

Summary

Nanobac Pharmaceuticals beats AtheroNova on 1 of the 1 factors compared between the two stocks.

China Botanic Pharmaceutical (OTCMKTS:CBPI) and Nanobac Pharmaceuticals (OTCMKTS:NNBP) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, dividends, analyst recommendations and profitability.

Earnings & Valuation

This table compares China Botanic Pharmaceutical and Nanobac Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Botanic PharmaceuticalN/AN/AN/AN/AN/A
Nanobac PharmaceuticalsN/AN/AN/AN/AN/A

Risk & Volatility

China Botanic Pharmaceutical has a beta of 17.09, indicating that its share price is 1,609% more volatile than the S&P 500. Comparatively, Nanobac Pharmaceuticals has a beta of -0.24, indicating that its share price is 124% less volatile than the S&P 500.

Profitability

This table compares China Botanic Pharmaceutical and Nanobac Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Botanic PharmaceuticalN/AN/AN/A
Nanobac PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations for China Botanic Pharmaceutical and Nanobac Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Botanic Pharmaceutical0000N/A
Nanobac Pharmaceuticals0000N/A

Summary

China Botanic Pharmaceutical beats Nanobac Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

China Dongsheng International (OTCMKTS:CDSG) and Nanobac Pharmaceuticals (OTCMKTS:NNBP) are both consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Valuation & Earnings

This table compares China Dongsheng International and Nanobac Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Dongsheng InternationalN/AN/AN/AN/AN/A
Nanobac PharmaceuticalsN/AN/AN/AN/AN/A

Risk and Volatility

China Dongsheng International has a beta of 13.38, indicating that its stock price is 1,238% more volatile than the S&P 500. Comparatively, Nanobac Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the S&P 500.

Profitability

This table compares China Dongsheng International and Nanobac Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Dongsheng InternationalN/AN/AN/A
Nanobac PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings for China Dongsheng International and Nanobac Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Dongsheng International0000N/A
Nanobac Pharmaceuticals0000N/A

Summary

China Dongsheng International beats Nanobac Pharmaceuticals on 1 of the 1 factors compared between the two stocks.


Nanobac Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Acusphere logo
ACUS
Acusphere
0.0$0.05flat$0.00N/A0.00Gap Down
Affymax logo
AFFY
Affymax
0.6$0.07flat$0.00N/A0.00Gap Up
ARYX
ARYx Therapeutics
0.0$0.01flat$0.00N/A0.00Gap Down
AHROQ
AtheroNova
0.0$0.02flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.07flat$0.00N/A0.00Gap Down
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.06flat$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.25flat$0.00$9.93 million4.20
DDXSQ
Diadexus
0.0$0.00flat$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00
FTCY
Global Future City
0.5$0.00flat$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$32.56flat$0.00N/A0.00Gap Down
HRBR
Harbor Diversified
0.0$1.84flat$0.00$263.61 million0.00High Trading Volume
IPAH
Interpharm
0.2$0.00flat$0.00N/A0.00Gap Up
IRBS
IR Biosciences
0.0$0.00flat$0.00N/A0.00
MBVXQ
MabVax Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Down
MYRX
Myrexis
0.5$0.05flat$0.00N/A0.00Gap Up
PARD
Poniard Pharmaceuticals
0.5$0.05flat$0.00N/A0.00Gap Down
SGTI
Shengtai Pharmaceutical
0.2$0.02flat$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00flat$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.05flat$0.00$26.09 million0.00Gap Up
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.03flat$0.00N/A0.00Gap Up
SYNI
Synvista Therapeutics
0.0$0.00flat$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00flat$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.01flat$0.00N/A0.00
VOQP
VioQuest Pharmaceuticals
0.0$0.01flat$0.00N/A0.00
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.